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Clinical trials are usually designed to meet registration requirements in developed countries, and do not
always address key concerns for use in developing countries. Four late-stage investigational new drugs –
rilpivirine, etravirine, raltegravir and maraviroc – show potential to improve antiretroviral therapy.
However, a number of issues could limit their use in developing countries, including dose selection,
treatment strategy, combination with other drugs, use in speciﬁc populations and reliance on expensive
tests. Key research questions relevant for developing countries need to be answered early in the drug
development process to ensure maximum beneﬁt for the majority.
Introduction
Although the majority of people infected with HIV/AIDS live in
the developing world, there are often long delays between the
registration of a new antiretroviral drug in the West and its
inclusion in national healthcare systems in developing countries.
For example, the World Health Organization (WHO) included
tenofovir in ﬁrst-line antiretroviral therapy for resource-limited
settings in 2006 [1], ﬁve years after the FDA registered it. As of May
2008, only three Africancountries have included tenofovir in their
guidelines for ﬁrst-line regimens (Namibia, Lesotho and Zambia).
Why does it take so long to integrate new life-saving drugs in
treatment guidelines of developing countries? Affordability and
timely drug registration are recognized issues [2], but another
limiting factor that is much more poorly recognized is the lack
of relevant studies providing evidence for added value above
existing treatment algorithms. We, and others, have argued that
this is intrinsically linked to the lack of proﬁtability in resource-
limited settings [2,3]: HIV-infected populations differ between
developed and developing countries, the latter including signiﬁ-
cant numbers of children, women of child-bearing age and people
coinfected with tuberculosis, malaria and other infectious dis-
eases. This paper focuses on four antiretroviral drugs that are
advanced in development or that have been recently approved
to provide an analysis of to what extent current research and
development of HIV drugs appropriately addresses the needs of
developing countries (Table 1).
Three drugs, maraviroc, raltegravir and etravirine, have been
approved by the FDA since mid-2007, while the fourth drug under
discussion here – rilpivirine – is currently the most advanced drug
in the HIV pipeline. The information presented in this paper is on
the basis of interviews conducted with scientiﬁc opinion leaders,
and a review of the literature. We used PubMed and the clinical
trials database of the US National Institutes of Health (http://
www.clinicaltrials.gov/) to search the terms ‘rilpivirine’, ‘tmc
278’, ‘maraviroc’, ‘raltegravir’, ‘etravirine’ and ‘tmc 125’. We also
contacted the originator companies (Tibotec, Merck and Pﬁzer) for
the four drugs under discussion with a series of questions. Tibotec
and Merck requested the signing of conﬁdentiality agreements
before providing information beyond what is already in the public
domain. We declined the signing of conﬁdentiality agreements
because we believe that it would have prevented starting an open
dialog in the scientiﬁc community. Pﬁzer did not respond.
Clinical development of antiretrovirals
Antiretrovirals are primarily made for developed country mar-
kets and clinical trials are designed to meet the requirements for
registration in these countries. Key research questions relevant
for resource-limited settings are often only raised long after a
drug has been registered and marketed in the USA and Europe.
The gap in the currently available knowledge relating to how
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antimalarial drugs and antiretrovirals interact [4] is a good
example: the latest WHO guidelines [1] do not provide evi-
dence-based guidance on how to use antimalarials together with
antiretrovirals, despite the fact that 80% of HIV-infected indi-
viduals live in regions where malaria is endemic (http://
www.who.int/malaria/malariandhivaids.html). This is in con-
trast to current practice in the developed world, where drug
regulatory authorities often insist that data regarding a drug’s
use in particular populations be submitted. For example, the FDA
[5] has included incentives and obligations to encourage the
submission of data for pediatric use since 1997, an initiative that
was ﬁnally adopted by the European Agency for the Evaluation of
Medicinal Products (EMEA) in January 2007 [6].
The arrival of antiretrovirals with new mechanisms of action
and, hence, greater potency against resistant strains points to a
potential shift in how HIV/AIDS will be treated in the future [7–
10]. The extent to which these innovations will beneﬁt the major-
ity of those affected by the disease who live in the developing
world will depend on the availability of relevant clinical data:
efﬁcacy in minority populations, interaction with drugs to treat
common coinfections and different formulations (combinations
and dosages). Moreover, in high-burden countries public health
authorities need cost-effectiveness data for optimal integration
into existing treatment algorithms. Thus there are considerations
both in terms of patient care (improved safety and efﬁcacy) and
public health (sustainability).
Rilpivirine is a second-generation non-nucleoside reverse-tran-
scriptase inhibitor (NNRTI) showing in vitro antiretroviral activity
up to 20 times greater than efavirenz or nevirapine, the two most
common drugs used in ﬁrst-line regimens in developing countries.
Rilpivirine is effective against HIV-1 variants with key NNRTI
mutations, and there is a high genetic barrier to the development
of rilpivirine resistance. Data from a 48-week Phase II trial show
noninferiority to efavirenz even at the lowest dose of 25 mg. From
a safety perspective the compound was found to have less central
nervous system side effects and a better lipid proﬁle than efavirenz
[8].
Etravirine is a non-nucleoside reverse-transcriptase inhibitor
with potent activity against HIV strains resistant to current
NNRTIs. It has been shown to be highly effective in treatment-
experienced patients in combination with other active com-
pounds [11].
Raltegravir is an integrase inhibitor, a new class of antiretrovir-
als showing in vitro activity against virus strains resistant to all
existent antiretroviral drugclasses. Licensing fortreatment-experi-
enced patients was granted in December 2007, and trials are
currently underway for treatment-naive (Phase II) patients
(http://www.fda.gov/oashi/aids/listserve/listserve2007.html).
Maraviroc belongs to the HIV entry inhibitors class, a new class
of drugs that act to block viral entry into the cell. Different HIV
clades use different coreceptors, either CCR5 or CXCR4, to bind to
CD4 cells. Maraviroc interacts speciﬁcally with CCR5, and its
efﬁcacy strongly depends on the CCR5 tropism at treatment
initiation [12].
Thefollowing points of importanceto developing countries will
be considered in this case study: dose selection, comparability and
compatibility with other ARVs, and use in speciﬁc populations.
Dose selection
Activepharmaceuticalingredientsconstitutethemaincostofdrug
manufacture[13].Indevelopedcountries,wheredrugsaresoldata
high proﬁt, this cost only represents a fraction of the market price.
In the developing world, where generic competition allows costs
to approach manufacturing costs, the amount of active pharma-
ceutical ingredient is crucial. The 75-mg dose of rilpivirine has
been selected for further development. Data presented at the CROI
meeting in 2007 [8] showed no signiﬁcant difference in efﬁcacy
between the 25, 75 and 150 mg doses. Virological (viral load
reductions and the percentage of patients with viral load below
50 copies) and immunological (increase in CD4 count) responses
were not signiﬁcantly different. Particularly for treatment-naı ¨ve
patients, formulating rilpivirine at a lower dose could reduce the
cost and signiﬁcantly enhance access in the developing world. In
addition to cost concerns, there is evidence that, at least for some
drugs (efavirenz, e.g. [14]), there is a correlation between plasma
drug concentration and the risk of developing toxicity. Therefore,
these lower doses should be tested in clinical studies (After this
paper was submitted, Tibotec announced they would include a
lower dose for rilpivirine in clinical trials.).
Treatment strategy
Tibotecisdevelopingrilpivirineforthetreatmentofantiretroviral-
naı ¨ve patients in combination with other antiretrovirals [15].
However, on the basis of its in vitro virological proﬁle and speciﬁc
pharmacokinetics it is reasonable to expect excellent safety and
efﬁcacy in treatment-experienced patients. Etravirine, a similar
compounddevelopedbythesamecompany,hasbeenshowntobe
highly effective in treatment-experienced patients, providing an
additional rationale for this hypothesis [11].
A proof-of-principle study with rilpivirine in treatment-experi-
enced patients was performed but results have not been made
public. Etravirine unfortunately has less favorable drug product
characteristics – high pill burden and a difﬁcult manufacturing
process using a speciﬁc spray dry technology – limiting its poten-
tial in the developing world [16]. Tibotec is the developer of both
of these new NNRTI compounds. Could they have economic
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TABLE 1
Drug class, presentation and approval status of four emerging antitretrovirals
Drug name Brand name ARV class Producer Presentation Approval status
Rilpivirine NNRTI Tibotec Phase III trial will be 75 mg
* Phase IIb
Etravirine Intelence NNRTI Tibotec 100 mg tablet US FDA approved 18/01/2008
Maraviroc Selzentry CCR5 inhibitor Pﬁzer 150 mg and 300 mg tablets US FDA approved 06/08/2007
Raltegravir Isentress Integrase inhibitor Merck 400 mg tablet US FDA approved 12/11/2007
*Since this paper was submitted, Tibotec announced that because of toxicity concerns they will investigate a lower dose (25 mg) in Phase III trials.
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reasonsforchoosingtoreserveonecompound forthetreatmentof
ARV-naı ¨ve and the other for the treatment of ARV-experienced
patients? On the basis of this development strategy, initial
approval of rilpivirine by regulatory authorities in the developed
world will probably limit the indication to the treatment of
ARV-naı ¨ve patients. We believe this will make it harder for
national regulatory authorities and guideline committees to
approve it for use in treatment-experienced populations.
Etravirine (also known as Intelence or TMC125) was approved
bytheFDA on18 January2008 foruse incombination withatleast
two other antiretroviral agents for the treatment of adults with
HIV-1 infection. Apart from being complex to manufacture, the
drug was recently granted a patent in India, which will greatly
limit the ability of Indian generics manufacturers to produce this
drug (http://www.kaisernetwork.org/daily_reports/rep_index.
cfm?DR_ID=50350).
Combination with other antiretrovirals
The clinical development plan for rilpivirine includes studies in
combination with tenofovir/emtricitabine, zidovudine/lamivu-
dine or abacavir/lamivudine. These form the backbone of ﬁrst-
line regimens in the developed world, and Tibotec hopes to show
added value over the existing NNRTIs.
In the developing world, however, there might be an interest in
preserving the ﬁrst generation of NNRTIs, such as efavirenz and
nevirapine, which are widely used and have proven efﬁcacy, and
reserve this second-generation compound for a later stage in the
treatment sequence. Only if baseline resistance in newly infected
individuals against efavirenz and nevirapine rises above a certain
threshold would it be justiﬁed to replace these drugs by newer
NNRTIs earlier in the treatment sequence. Additionally, for
patients who have been treated with NNRTIs and NRTIs (nucleo-
tide reverse transcriptase inhibitors), the efﬁcacy of rilpivirine may
be lower unless it is combined with other fully active drugs such as
boosted protease inhibitors [17,18].
Currently, boosted protease inhibitors are the standard, indeed
the only, choice for second-line treatment. Clinical data for ralte-
gravir show good efﬁcacy in highly treatment-experienced
patients [19]. Preliminary pharmacokinetic data have shown an
increase in the plasma concentration of raltegravir in the presence
of atazanavir. This is because atazanavir is a strong inhibitor of
UDP glucuronosyltransferase (UGT1A1), which is a mediator of
raltegravir metabolization [20]. Thus, this combination may allow
for an unboosted second-line regimen for NNRTI-dosed patients.
Twocharacteristicsofcurrentﬁrst-linetreatmentregimenshave
facilitated the scale-up of antiretroviral therapy in the developing
world: low cost and simplicity (three-in-one ﬁxed-dose combina-
tions). Second-line antiretroviral therapy should be as affordable
and simple as ﬁrst-line regimens.
Raltegravir interacts negligibly with the NNRTI efavirenz, pro-
viding support for the approach of using the similar NNRTI
rilpivirine in combination with raltegravir. It will be equally
important to perform additional formulation work that provides
a slow-release formulation that could lead to the development of a
ﬁxed-dose combination that would only need to be taken once a
day.Theuse,atthisstage, ofraltegravirandrilpivirinewoulddelay
recourse to any of the boosted protease inhibitors, which have a
higher complexity of drug–drug interactions, a higher pill burden
and higher cost, all of which pose major challenges for their
widespread use in resource-limited settings.
Use in speciﬁc populations
Currently, the limited human pharmacokinetic data [16] that are
available do not support the use of rilpivirine together with
rifampicin (a core drug to treat tuberculosis) because bioavailabil-
ityofrilpivirineisreducedby80%[21].Thisposesamajorproblem
for its use in HIV/TB coinfected individuals that represent a sig-
niﬁcant proportion of the HIV population in resource-limited
settings. According to WHO up to 50% of TB patients in African
countries are HIV positive (http://www.who.int/tb/challenges/
hiv/facts/en/index.html), and this ﬁgure is rising to over 90% in
some settings. This is another example of the importance of taking
developing world considerations into account when undertaking
clinical studies. Speciﬁc research needs to be incorporated in the
development plans of new compounds, for example, to address
whether rilpivirine is compatible with rifampicin in vivo, and this
issue is further discussed in our concluding remarks.
This subject is also illustrated by the use (or non-use) of the new
CCR5 inhibitor Maraviroc in resource-limited settings. Maraviroc
is only fully active against HIV clades using the CCR5 coreceptor,
and it is recommended that a viral tropism assay (Troﬁle
TM) is used
to determine which HIV clade is present before starting Maraviroc
treatment. FDA approved Maraviroc for use in treatment-experi-
enced patients infected only with CCR5-tropic HIV-1 in July 2007,
and EMEA has adopted a positive opinion [22] with the recom-
mendation to grant a marketing authorization with the same
indication. However, the tropism test is not widely available
(currently it is only performed in CA, USA), expensive (US$
1960; Mongram Biosciences as of August 2007) and is less than
90%speciﬁc.Moreover,complexinteractionswithPIsandNNRTIs
are observed and dose adjustments warranted [23].
In rural resource-limited settings where basic monitoring tests
are not always available it would be unrealistic to introduce new
drugs that require additional complex laboratory tests before they
can be used, particularly if the test is expensive and only available
in the USA. Although an important treatment addition for high
resource settings, this is an innovation that probably will not
beneﬁt people in resource-limited settings any time soon. (The
costs of the tropism test alone are 20 times the current annual
spend on lab tests per patient in South Africa [24].)
Conclusions
Simpliﬁed ﬁrst-line regimens have been a cornerstone to scale up
ART in resource-limited settings. The priority today is to develop
more robust ﬁrst- and second-line regimens that are simple,
affordable and compatible with patient and disease proﬁles in
the developing world.
Antiretrovirals with a new mechanism of action are heralded in
the developed world for their potential to change the treatment
paradigm. If resource-poor settings are to beneﬁt maximally from
these innovations we need to ensure that robust data from clinical
trials support their use in these environments. Necessary research
includes lower dose efﬁcacy studies with rilpivirine, interaction
studies between raltegravir and rilpivirine, formulation work for a
once daily dosing schedule of raltegravir, and concentration and
effect (pharmacokinetic–pharmacodynamic) data for this regi-
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men. Studies should also compare the efﬁcacy of rilpivirine and/or
raltegravir-containing regimens against current WHO recommen-
dations for second-line therapy.
Our analysis was limited by lack of free access to company
information.Untilsuchinformationismademorefreelyavailable,
the rationale of companies’ clinical development decisions will
remain unclear and the scientiﬁc community will be unable to
advise and contribute with research in resource-poor settings. In
addition to the four drugs analyzed here, all other antiretroviral
drugs currently in development should be reviewed for their
potential use in resource-limited settings so that relevant trials
can be included early on in clinical development. This will be
possible only if the scientiﬁc community has better access to
information and if companies feel accountable for the extent to
which their clinical development plans will address high- and low-
resource settings.
Pharmaceutical companies, in this case Merck (raltegravir) and
Johnson & Johnson/Tibotec (rilpivirine), have a responsibility to
initiate and contribute to studies that are relevant for resource-
limited settings if they are seriously committed to contribute to
global health. However, this is not their job alone. The scientiﬁc
community should also play a bigger part than is the case today in
carrying out such studies that are of global public beneﬁt. Public
funding could be sought for such research as long as there is very
clear agreement between the private and the public sector on
future accessibility in terms of price, in-country registration and
possible licensing to other producers [25].
Regulatory agencies also have an important part to play by
requiring data for relevant populations in different settings as part
of the drug approval process. Proactive steps should be taken by
the originator companies that hold the intellectual property and
clinical data for the compounds.
The issues outlined for these emerging antiretrovirals are a
symptom of the general concern that the drug research and
development agenda rarely includes the speciﬁc concerns of the
developing world, where 90% of people with HIV/AIDS reside [26].
Greater consideration should be given by all stakeholders to
ensure that promising new drugs are made as affordable as possi-
ble, as soon as possible. To date, the history of antiretroviral drug
development has shown that these two basic needs of the devel-
oping world are usually only considered long after a new medicine
has been available in the West, if they are considered at all.
Although, for some diseases, the creation of product develop-
mentpartnershipsishelpingtoaddressenormousinnovationgaps
[27], the situation for HIV drug development is different because
HIV drug development for the Western market remains proﬁtable.
Considerable international funding is available to support HIV/
AIDS care in the developing world and this has created a viable
low-cost, high-volume market for products aimed at developing
countries. Pharmaceutical companies should make the develop-
ment and delivery of effective and affordable medicines for high-
and low-resource settings an integral part of their business model.
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